1
|
Huang HJ, Sarzsinszky E, Vrtala S. House dust mite allergy: The importance of house dust mite allergens for diagnosis and immunotherapy. Mol Immunol 2023; 158:54-67. [PMID: 37119758 DOI: 10.1016/j.molimm.2023.04.008] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2023] [Revised: 04/11/2023] [Accepted: 04/14/2023] [Indexed: 05/01/2023]
Abstract
House dust mite (HDM) allergy belongs to the most important allergies and affects approximately 65-130 million people worldwide. Additionally, untreated HDM allergy may lead to the development of severe disease manifestations such as atopic dermatitis or asthma. Diagnosis and immunotherapy of HDM allergic patients are well established but are often hampered by the use of mite extracts that are of bad quality and lack important allergens. The use of individual allergens seems to be a promising alternative to natural allergen extracts, since they represent well-defined components that can easily be produced and quantified. However, a thorough characterization of the individual allergens is required to determine their clinical relevance and to identify those allergens that are required for correct diagnosis of HDM allergy and for successful immunotherapy. This review gives an update on the individual HDM allergens and their benefits for diagnosis and immunotherapy of HDM allergic patients.
Collapse
Affiliation(s)
- Huey-Jy Huang
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
| | - Eszter Sarzsinszky
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
| | - Susanne Vrtala
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.
| |
Collapse
|
2
|
Vrtala S. Allergene von Hausstaub- und Vorratsmilben. ALLERGO JOURNAL 2022. [DOI: 10.1007/s15007-022-5640-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|
3
|
Design, production and immunomodulatory potency of a novel allergen bioparticle. PLoS One 2020; 15:e0242867. [PMID: 33259521 PMCID: PMC7707610 DOI: 10.1371/journal.pone.0242867] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2020] [Accepted: 11/10/2020] [Indexed: 02/08/2023] Open
Abstract
Allergen immunotherapy (AIT) is the only disease-modifying treatment with evidence for sustained efficacy. However, it is poorly developed compared to symptomatic drugs. The main reasons come from treatment duration implying monthly injections during 3 to 5 years or daily sublingual use, and the risk of allergic side-effects. To become a more attractive alternative to lifelong symptomatic drug use, improvements to AIT are needed. Among the most promising new immunotherapy strategies is the use of bioparticles for the presentation of target antigen to the immune system as they can elicit strong T cell and B cell immune responses. Virus-like particles (VLPs) are a specific class of bioparticles in which the structural and immunogenic constituents are from viral origin. However, VLPs are ill-suited for use in AIT as their antigenicity is linked to structure. Recently, synthetic biology has been used to produce artificial modular bioparticles, in which supramolecular assemblies are made of elements from heterogeneous biological sources promoting the design and use of in vivo-assembling enveloped bioparticles for viral and non-viral antigens presentation. We have used a coiled-coil hybrid assembly for the design of an enveloped bioparticle (eBP) that present trimers of the Der p 2 allergen at its surface, This bioparticle was produced as recombinant and in vivo assembled eBPs in plant. This allergen biotherapeutic was used to demonstrate i) the capacity of plants to produce synthetic supramolecular allergen bioparticles, and ii) the immunomodulatory potential of naturally-assembled allergen bioparticles. Our results show that allergens exposed on eBPs induced a very strong IgG response consisting predominantly of IgG2a in favor of the TH1 response. Finally, our results demonstrate that rDer p 2 present on the surface of BPs show a very limited potential to stimulate the basophil degranulation of patient allergic to this allergen which is predictive of a high safety potential.
Collapse
|
4
|
Smargiasso N, Nader J, Rioux S, Mazzucchelli G, Boutry M, De Pauw E, Chaumont F, Navarre C. Exploring the N-Glycosylation Profile of Glycoprotein B from Human Cytomegalovirus Expressed in CHO and Nicotiana tabacum BY-2 Cells. Int J Mol Sci 2019; 20:E3741. [PMID: 31370181 PMCID: PMC6696289 DOI: 10.3390/ijms20153741] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2019] [Revised: 07/23/2019] [Accepted: 07/30/2019] [Indexed: 02/01/2023] Open
Abstract
The ability to control the glycosylation pattern of recombinant viral glycoproteins represents a major prerequisite before their use as vaccines. The aim of this study consisted of expressing the large soluble ectodomain of glycoprotein B (gB) from Human Cytomegalovirus (HMCV) in Nicotiana tabacum Bright Yellow-2 (BY-2) suspension cells and of comparing its glycosylation profile with that of gB produced in Chinese hamster ovary (CHO) cells. gB was secreted in the BY-2 culture medium at a concentration of 20 mg/L and directly purified by ammonium sulfate precipitation and size exclusion chromatography. We then measured the relative abundance of N-glycans present on 15 (BY-2) and 17 (CHO) out of the 18 N-sites by multienzymatic proteolysis and mass spectrometry. The glycosylation profile differed at each N-site, some sites being occupied exclusively by oligomannosidic type N-glycans and others by complex N-glycans processed in some cases with additional Lewis A structures (BY-2) or with beta-1,4-galactose and sialic acid (CHO). The profiles were strikingly comparable between BY-2- and CHO-produced gB. These results suggest a similar gB conformation when glycoproteins are expressed in plant cells as site accessibility influences the glycosylation profile at each site. These data thus strengthen the BY-2 suspension cultures as an alternative expression system.
Collapse
Affiliation(s)
- Nicolas Smargiasso
- Mass Spectrometry Laboratory-MolSys, GIGA Proteomics Facility, University of Liège, 4000 Liège, Belgium
| | - Joseph Nader
- Louvain Institute for Biomolecular Science and Technology, UCLouvain, 1348 Louvain-la-Neuve, Belgium
| | | | - Gabriel Mazzucchelli
- Mass Spectrometry Laboratory-MolSys, GIGA Proteomics Facility, University of Liège, 4000 Liège, Belgium
| | - Marc Boutry
- Louvain Institute for Biomolecular Science and Technology, UCLouvain, 1348 Louvain-la-Neuve, Belgium
| | - Edwin De Pauw
- Mass Spectrometry Laboratory-MolSys, GIGA Proteomics Facility, University of Liège, 4000 Liège, Belgium
| | - François Chaumont
- Louvain Institute for Biomolecular Science and Technology, UCLouvain, 1348 Louvain-la-Neuve, Belgium.
| | - Catherine Navarre
- Louvain Institute for Biomolecular Science and Technology, UCLouvain, 1348 Louvain-la-Neuve, Belgium
| |
Collapse
|
5
|
Leite ML, Sampaio KB, Costa FF, Franco OL, Dias SC, Cunha NB. Molecular farming of antimicrobial peptides: available platforms and strategies for improving protein biosynthesis using modified virus vectors. AN ACAD BRAS CIENC 2018; 91:e20180124. [PMID: 30365717 DOI: 10.1590/0001-3765201820180124] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2018] [Accepted: 06/07/2018] [Indexed: 11/22/2022] Open
Abstract
The constant demand for new antibiotic drugs has driven efforts by the scientific community to prospect for peptides with a broad spectrum of action. In this context, antimicrobial peptides (AMPs) have acquired great scientific importance in recent years due to their ability to possess antimicrobial and immunomodulatory activity. In the last two decades, plants have attracted the interest of the scientific community and industry as regards their potential as biofactories of heterologous proteins. One of the most promising approaches is the use of viral vectors to maximize the transient expression of drugs in the leaves of the plant Nicotiana benthamiana. Recently, the MagnifectionTM expression system was launched. This sophisticated commercial platform allows the assembly of the viral particle in leaf cells and the systemic spread of heterologous protein biosynthesis in green tissues caused by Agrobacterium tumefaciens "gene delivery method". The system also presents increased gene expression levels mediated by potent viral expression machinery. These characteristics allow the mass recovery of heterologous proteins in the leaves of N. benthamiana in 8 to 10 days. This system was highly efficient for the synthesis of different classes of pharmacological proteins and contains enormous potential for the rapid and abundant biosynthesis of AMPs.
Collapse
Affiliation(s)
- Michel L Leite
- Centro de Análises Proteômicas e Bioquímicas, Universidade Católica de Brasília/UCB, SGAN 916, Modulo B, Bloco C, 70790-160 Brasilia, DF, Brazil
- Pós-Graduação em Ciências Genômicas e Biotecnologia, Centro de Análises Proteômicas e Bioquímicas, Universidade Católica de Brasília/UCB, SGAN 916, Modulo B, Bloco C, 70790-160 Brasilia, DF, Brazil
| | - Kamila B Sampaio
- Centro de Análises Proteômicas e Bioquímicas, Universidade Católica de Brasília/UCB, SGAN 916, Modulo B, Bloco C, 70790-160 Brasilia, DF, Brazil
- Pós-Graduação em Ciências Genômicas e Biotecnologia, Centro de Análises Proteômicas e Bioquímicas, Universidade Católica de Brasília/UCB, SGAN 916, Modulo B, Bloco C, 70790-160 Brasilia, DF, Brazil
| | - Fabrício F Costa
- Centro de Análises Proteômicas e Bioquímicas, Universidade Católica de Brasília/UCB, SGAN 916, Modulo B, Bloco C, 70790-160 Brasilia, DF, Brazil
- Cancer Biology and Epigenomics Program, Northwestern University's Feinberg School of Medicine, 60611, Chicago IL, USA
- Genomic Enterprise, 2405 N. Sheffield Av., 14088, 60614, Chicago, IL, USA
- MATTER Chicago, 222 W. Merchandise Mart Plaza, 12th Floor, 60654, Chicago, IL, USA
- The Founder Institute, 3337 El Camino Real, 94306, Palo Alto, CA USA
| | - Octávio L Franco
- Centro de Análises Proteômicas e Bioquímicas, Universidade Católica de Brasília/UCB, SGAN 916, Modulo B, Bloco C, 70790-160 Brasilia, DF, Brazil
- Pós-Graduação em Ciências Genômicas e Biotecnologia, Centro de Análises Proteômicas e Bioquímicas, Universidade Católica de Brasília/UCB, SGAN 916, Modulo B, Bloco C, 70790-160 Brasilia, DF, Brazil
- S-Inova Biotech, Pós-Graduação em Biotecnologia, Universidade Católica Dom Bosco, Av. Tamandaré, 6000, Jardim Seminário, 79117-010 Campo Grande, MS, Brazil
| | - Simoni C Dias
- Centro de Análises Proteômicas e Bioquímicas, Universidade Católica de Brasília/UCB, SGAN 916, Modulo B, Bloco C, 70790-160 Brasilia, DF, Brazil
- Pós-Graduação em Ciências Genômicas e Biotecnologia, Centro de Análises Proteômicas e Bioquímicas, Universidade Católica de Brasília/UCB, SGAN 916, Modulo B, Bloco C, 70790-160 Brasilia, DF, Brazil
| | - Nicolau B Cunha
- Centro de Análises Proteômicas e Bioquímicas, Universidade Católica de Brasília/UCB, SGAN 916, Modulo B, Bloco C, 70790-160 Brasilia, DF, Brazil
- Pós-Graduação em Ciências Genômicas e Biotecnologia, Centro de Análises Proteômicas e Bioquímicas, Universidade Católica de Brasília/UCB, SGAN 916, Modulo B, Bloco C, 70790-160 Brasilia, DF, Brazil
| |
Collapse
|
6
|
da Cunha NB, Cobacho NB, Viana JFC, Lima LA, Sampaio KBO, Dohms SSM, Ferreira ACR, de la Fuente-Núñez C, Costa FF, Franco OL, Dias SC. The next generation of antimicrobial peptides (AMPs) as molecular therapeutic tools for the treatment of diseases with social and economic impacts. Drug Discov Today 2017; 22:234-248. [PMID: 27890668 PMCID: PMC7185764 DOI: 10.1016/j.drudis.2016.10.017] [Citation(s) in RCA: 117] [Impact Index Per Article: 16.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2016] [Revised: 10/28/2016] [Accepted: 10/31/2016] [Indexed: 12/02/2022]
Abstract
Anti-infective drugs have had a key role in the contemporary world, contributing to dramatically decrease mortality rates caused by infectious diseases worldwide. Antimicrobial peptides (AMPs) are multifunctional effectors of the innate immune system of mucosal surfaces and present antimicrobial activity against a range of pathogenic viruses, bacteria, and fungi. However, the discovery and development of new antibacterial drugs is a crucial step to overcome the great challenge posed by the emergence of antibiotic resistance. In this review, we outline recent advances in the development of novel AMPs with improved antimicrobial activities that were achieved through characteristic structural design. In addition, we describe recent progress made to overcome some of the major limitations that have hindered peptide biosynthesis.
Collapse
Affiliation(s)
- Nicolau B da Cunha
- Center of Proteomic and Biochemical Analysis, Post-Graduation in Genomic Sciences and Biotechnology Universidade Católica de Brasília UCB, SGAN 916, Modulo B, Bloco C, 70.790-160 Brasilia, DF, Brazil; Genomic Sciences and Biotechnology Program - Universidade Católica de Brasília UCB, SGAN 916, Modulo B, Bloco C, 70.790-160 Brasilia, DF, Brazil
| | - Nicole B Cobacho
- Center of Proteomic and Biochemical Analysis, Post-Graduation in Genomic Sciences and Biotechnology Universidade Católica de Brasília UCB, SGAN 916, Modulo B, Bloco C, 70.790-160 Brasilia, DF, Brazil
| | - Juliane F C Viana
- Center of Proteomic and Biochemical Analysis, Post-Graduation in Genomic Sciences and Biotechnology Universidade Católica de Brasília UCB, SGAN 916, Modulo B, Bloco C, 70.790-160 Brasilia, DF, Brazil; Universidade Ceuma, Rua Josué Montello, 1, 65060-645 São Luís, MA, Brazil
| | - Loiane A Lima
- Center of Proteomic and Biochemical Analysis, Post-Graduation in Genomic Sciences and Biotechnology Universidade Católica de Brasília UCB, SGAN 916, Modulo B, Bloco C, 70.790-160 Brasilia, DF, Brazil
| | - Kamila B O Sampaio
- Center of Proteomic and Biochemical Analysis, Post-Graduation in Genomic Sciences and Biotechnology Universidade Católica de Brasília UCB, SGAN 916, Modulo B, Bloco C, 70.790-160 Brasilia, DF, Brazil
| | - Stephan S M Dohms
- Center of Proteomic and Biochemical Analysis, Post-Graduation in Genomic Sciences and Biotechnology Universidade Católica de Brasília UCB, SGAN 916, Modulo B, Bloco C, 70.790-160 Brasilia, DF, Brazil
| | - Arthur C R Ferreira
- Center of Proteomic and Biochemical Analysis, Post-Graduation in Genomic Sciences and Biotechnology Universidade Católica de Brasília UCB, SGAN 916, Modulo B, Bloco C, 70.790-160 Brasilia, DF, Brazil
| | - César de la Fuente-Núñez
- Synthetic Biology Group, MIT Synthetic Biology Center, Massachusetts Institute of Technology, 02139 Cambridge, MA, USA; Research Laboratory of Electronics, Massachusetts Institute of Technology, 02139 Cambridge, MA, USA; Department of Biological Engineering, Massachusetts Institute of Technology, 02139 Cambridge, MA, USA; Department of Electrical Engineering and Computer Science, Massachusetts Institute of Technology, 02142 Cambridge, MA, USA; Broad Institute of MIT and Harvard, 02142 Cambridge, MA, USA; Harvard Biophysics Program, Harvard University, 02115 Boston, MA, USA
| | - Fabrício F Costa
- Genomic Sciences and Biotechnology Program - Universidade Católica de Brasília UCB, SGAN 916, Modulo B, Bloco C, 70.790-160 Brasilia, DF, Brazil.
| | - Octávio L Franco
- Center of Proteomic and Biochemical Analysis, Post-Graduation in Genomic Sciences and Biotechnology Universidade Católica de Brasília UCB, SGAN 916, Modulo B, Bloco C, 70.790-160 Brasilia, DF, Brazil; Genomic Sciences and Biotechnology Program - Universidade Católica de Brasília UCB, SGAN 916, Modulo B, Bloco C, 70.790-160 Brasilia, DF, Brazil; S-Inova Biotech, Post-Graduation in Biotechnology, Universidade Católica Dom Bosco, 79117-900 Campo Grande, MS, Brazil
| | - Simoni C Dias
- Center of Proteomic and Biochemical Analysis, Post-Graduation in Genomic Sciences and Biotechnology Universidade Católica de Brasília UCB, SGAN 916, Modulo B, Bloco C, 70.790-160 Brasilia, DF, Brazil; Genomic Sciences and Biotechnology Program - Universidade Católica de Brasília UCB, SGAN 916, Modulo B, Bloco C, 70.790-160 Brasilia, DF, Brazil
| |
Collapse
|
7
|
Abstract
As investigations into the innate immune responses that lead to allergic sensitization become better defined, there is a need to determine how allergens could interact with pattern recognition receptors that bind non-proteinaceous moieties. Many important allergens are not covalently bound to lipid or carbohydrate, but have structures belonging to lipid, glycan and glycolipid-binding families. These include ML-domain proteins, lipopolysaccharide-binding/cell permeability-increasing proteins, von Ebner gland lipocalins, salivary lipocalins/major urinary proteins, plant pathogenesis-related proteins PR-5 and -10, uteroglobins, non-specific lipid transfer proteins, large lipid transfer proteins and proteins with chitin and other carbohydrate-binding modules. The binding expected is overviewed with regard to importance of the allergens and their ability to elicit responses proposed from experimental models. The evidence compiled showing that allergens from the same source sensitize for different types of adaptive immune responses supports the concept that individual allergens within these sources have their own distinctive interactions with innate immunity.
Collapse
|
8
|
Abstract
Activation of receptors of the innate immune system is a critical step in the initiation of immune responses. It has been shown that dominant allergens have properties that could allow them to interact with toll-like and C-type lectin receptors to favour Th2-biased responses and many bind lipids and glycans that could associate with ligands to mimic pathogen-associated microbial patterns. In accord with the proposed allergen-specific innate interactions it has been shown that the immune responses to different allergens and antigens from the same source are not necessarily coordinately regulated.
Collapse
Affiliation(s)
- W R Thomas
- Centre for Child Health Research, University of Western Australia, Telethon Institute for Child Health Research, Subiaco, Western Australia, Australia.
| |
Collapse
|
9
|
Marconi G, Albertini E, Mari A, Palazzo P, Porceddu A, Raggi L, Bolis L, Lancioni H, Palomba A, Lucentini L, Lanfaloni L, Marcucci F, Falcinelli M, Panara F. In planta expression of a mature Der p 1 allergen isolated from an Italian strain of Dermatophagoides pteronyssinus. Transgenic Res 2012; 21:523-35. [PMID: 21904913 DOI: 10.1007/s11248-011-9551-5] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2009] [Accepted: 08/25/2011] [Indexed: 10/17/2022]
Abstract
European (Dermatophagoides pteronyssinus) and American (Dermatophagoides farinae) house dust mite species are considered the most common causes of asthma and allergic symptoms worldwide. Der p 1 protein, one of the main allergens of D. pteronyssinus, is found in high concentration in mites faecal pellets, which can became easily airborne and, when inhaled, can cause perennial rhinitis and bronchial asthma. Here we report the isolation of the Der p 1 gene from an Italian strain of D. pteronyssinus and the PVX-mediated expression of its mature form (I-rDer p 1) in Nicotiana benthamiana plants. Human sera from characterized allergic patients were used for IgE binding inhibition assays to test the immunological reactivity of I-rDer p 1 produced in N. benthamiana plants. The binding properties of in planta produced I-rDer p 1 versus the IgE of patients sera were comparable to those obtained on Der p 1 preparation immobilized on a microarray. In this paper we provide a proof of concept for the production of an immunologically active form of Der p 1 using a plant viral vector. These results pave the way for the development of diagnostic allergy tests based on in planta produced allergens.
Collapse
Affiliation(s)
- Gianpiero Marconi
- Dipartimento di Biologia Applicata, University of Perugia, Borgo XX Giugno 74, 06121 Perugia, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Ullisch DA, Müller CA, Maibaum S, Kirchhoff J, Schiermeyer A, Schillberg S, Roberts JL, Treffenfeldt W, Büchs J. Comprehensive characterization of two different Nicotiana tabacum cell lines leads to doubled GFP and HA protein production by media optimization. J Biosci Bioeng 2012; 113:242-8. [PMID: 22055919 DOI: 10.1016/j.jbiosc.2011.09.022] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2011] [Revised: 09/21/2011] [Accepted: 09/29/2011] [Indexed: 11/19/2022]
Abstract
For over two decades, plant cell cultures have been a promising research platform to express recombinant and therapeutic proteins such as hormones, growth factors, full-size antibodies and antigens. Chosen as a good host for manufacturing recombinant proteins, the Nicotiana tabacum L. cv. Bright Yellow 2 (BY-2) cell line has been studied in shake flasks by offline analysis of only a few growth parameters. The objective of this study is to comprehensively characterize the growth of a transgenic BY-2 cell line and to investigate the expression profile of the model protein GFP. Based on the correlations between nutrient consumption, cell growth and product formation, the intention is to improve the standard MS-medium. Hereby, multiple growth parameters were analyzed offline and online by using a respiration activity monitoring system (RAMOS). A reproducibly observed shift of the oxygen transfer rate (OTR) could be identified to indicate ammonium depletion in the medium. Concurrent with this ammonium depletion, the total protein concentration began to decrease. After the MS-medium was improved, the GFP concentration nearly doubled. When this improved ammonium enriched medium was applied to another transgenic tobacco cell line similar improvements to the amount of the glycoprotein influenza hemagglutinin (HA) produced by Nicotiana tabacum NT-1 cells could be achieved. Ultimately, this combined offline and online analysis can be successfully used for further cell line characterization and media optimization to improve growth and boost target product formation.
Collapse
Affiliation(s)
- David A Ullisch
- RWTH Aachen University, AVT - Biochemical Engineering, Worringer Weg 1, 52056 Aachen, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Bordas-Le Floch V, Bussières L, Airouche S, Lautrette A, Bouley J, Berjont N, Horiot S, Huet A, Jain K, Lemoine P, Chabre H, Batard T, Mascarell L, Baron-Bodo V, Tourdot S, Nony E, Moingeon P. Expression and characterization of natural-like recombinant Der p 2 for sublingual immunotherapy. Int Arch Allergy Immunol 2012; 158:157-67. [PMID: 22286395 DOI: 10.1159/000331143] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2011] [Accepted: 07/25/2011] [Indexed: 01/30/2023] Open
Abstract
BACKGROUND Recombinant allergens with a native conformation represent an alternative to natural extracts for immunotherapy and diagnostic purposes. METHODS We produced the Der p 2 mite allergen in Pichia pastoris and Escherichia coli. After purification by cation exchange chromatography, recombinant molecules were compared to their natural counterpart based upon structural (disulfide bonds, secondary structure, thermal stability) and immunological properties (antibody reactivity, basophil and T cell activation, tolerance induction in a murine sublingual immunotherapy model). RESULTS The Der p 2.0101 isoform was confirmed to be prevalent in Dermatophagoides pteronyssinus extracts. It was then produced as a secreted molecule in P. pastoris or refolded from E. coli inclusion bodies. The yeast-expressed rDer p 2 molecule exhibits a natural-like disulfide bridge distribution and secondary structure, whereas the E. coli-derived rDer p 2 presents some heterogeneity in cysteine bonds and a lower stability following thermal stress. The two recombinant as well as natural Der p 2 molecules exhibit comparable IgE recognition and activate basophil and CD4+ T cells. Sublingual immunotherapy of nDer p 2- sensitized mice using either one of the rDer p 2 molecules efficiently decreases airway hyperresponsiveness as well as Th2 responses. CONCLUSIONS Natural and recombinant Der p 2 molecules produced in P. pastoris and E. coli exhibit comparable immunological properties despite distinct structural features. Natural-like cysteine pairing is a critical parameter to identify stable, well-folded and homogenous proteins appropriate for immunotherapy and diagnostic purposes.
Collapse
|
12
|
Goulet C, Khalf M, Sainsbury F, D'Aoust MA, Michaud D. A protease activity-depleted environment for heterologous proteins migrating towards the leaf cell apoplast. PLANT BIOTECHNOLOGY JOURNAL 2012; 10:83-94. [PMID: 21895943 DOI: 10.1111/j.1467-7652.2011.00643.x] [Citation(s) in RCA: 48] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/24/2023]
Abstract
Recombinant proteins face major constraints along the plant cell secretory pathway, including proteolytic processing compromising their structural integrity. Here, we demonstrate the potential of protease inhibitors as in situ stabilizing agents for recombinant proteins migrating towards the leaf apoplast. Genomic data for Arabidopsis, rice and Nicotiana spp. were assessed to determine the relative incidence of protease families in the cell secretory pathway. Transient expression assays with the model platform Nicotiana benthamiana were then performed to test the efficiency of protease inhibitors in stabilizing proteins targeted to the apoplast. Current genomic data suggest the occurrence of proteases from several families along the secretory pathway, including A1 and A22 Asp proteases; C1A and C13 Cys proteases; and S1, S8 and S10 Ser proteases. In vitro protease assays confirmed the presence of various proteases in N. benthamiana leaves, notably pointing to the deposition of A1- and S1-type activities preferentially in the apoplast. Accordingly, transient expression and secretion of the A1/S1 protease inhibitor, tomato cathepsin D inhibitor (SlCDI), negatively altered A1 and S1 protease activities in this cell compartment, while increasing the leaf apoplast protein content by ∼45% and improving the accumulation of a murine diagnostic antibody, C5-1, co-secreted in the apoplast. SlCYS9, an inhibitor of C1A and C13 Cys proteases, had no impact on the apoplast proteases and protein content, but stabilized C5-1 in planta, presumably upstream in the secretory pathway. These data confirm, overall, the potential of protease inhibitors for the in situ protection of recombinant proteins along the plant cell secretory pathway.
Collapse
Affiliation(s)
- Charles Goulet
- Département de phytologie, Université Laval, Pavillon des Services (INAF), Québec, QC, Canada
| | | | | | | | | |
Collapse
|
13
|
Huang TK, McDonald KA. Bioreactor systems for in vitro production of foreign proteins using plant cell cultures. Biotechnol Adv 2011; 30:398-409. [PMID: 21846499 DOI: 10.1016/j.biotechadv.2011.07.016] [Citation(s) in RCA: 74] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2011] [Revised: 06/17/2011] [Accepted: 07/25/2011] [Indexed: 12/31/2022]
Abstract
Plant cells have been demonstrated to be an attractive heterologous expression host (using whole plants and in vitro plant cell cultures) for foreign protein production in the past 20years. In recent years in vitro liquid cultures of plant cells in a fully contained bioreactor have become promising alternatives to traditional microbial fermentation and mammalian cell cultures as a foreign protein expression platform, due to the unique features of plant cells as a production host including product safety, cost-effective biomanufacturing, and the capacity for complex protein post-translational modifications. Heterologous proteins such as therapeutics, antibodies, vaccines and enzymes for pharmaceutical and industrial applications have been successfully expressed in plant cell culture-based bioreactor systems including suspended dedifferentiated plant cells, moss, and hairy roots, etc. In this article, the current status and emerging trends of plant cell culture for in vitro production of foreign proteins will be discussed with emphasis on the technological progress that has been made in plant cell culture bioreactor systems.
Collapse
Affiliation(s)
- Ting-Kuo Huang
- Department of Chemical Engineering and Materials Science, University of California, Davis, CA 95616, United States
| | | |
Collapse
|
14
|
Su CF, Kuo IC, Chen PW, Huang CH, Seow SV, Chua KY, Yu SM. Characterization of an immunomodulatory Der p 2-FIP-fve fusion protein produced in transformed rice suspension cell culture. Transgenic Res 2011; 21:177-92. [DOI: 10.1007/s11248-011-9518-6] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2010] [Accepted: 04/26/2011] [Indexed: 11/29/2022]
|
15
|
Xu J, Ge X, Dolan MC. Towards high-yield production of pharmaceutical proteins with plant cell suspension cultures. Biotechnol Adv 2011; 29:278-99. [DOI: 10.1016/j.biotechadv.2011.01.002] [Citation(s) in RCA: 137] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2010] [Revised: 12/24/2010] [Accepted: 01/02/2011] [Indexed: 12/16/2022]
|
16
|
Franconi R, Demurtas OC, Massa S. Plant-derived vaccines and other therapeutics produced in contained systems. Expert Rev Vaccines 2010; 9:877-92. [PMID: 20673011 DOI: 10.1586/erv.10.91] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2023]
Abstract
The use of contained plant systems for the production of biopharmaceuticals represents a powerful alternative to current methods, combining the benefits of whole-plant systems and cell cultures. In vitro contained production systems include plant cell suspensions, hairy root cultures, novel plants grown in contained conditions and microalgae. These systems show intrinsic advantages, such as control over growth conditions, production in compliance with good manufacturing practice and avoidance of political resistance to the release of genetically modified field crops. At present, one of the two plant-produced vaccine-related products that have gone all the way through production and regulatory hurdles derives from tobacco cell suspensions, and the second is a human therapeutic enzyme, which is expected to reach commercial development soon and derives from carrot suspension cells. In the future, several other products from contained systems are expected to reach the clinical trial stage.
Collapse
Affiliation(s)
- Rosella Franconi
- Italian National Agency for New Technologies, UTBIORAD, CR Casaccia, Rome, Italy.
| | | | | |
Collapse
|
17
|
Tremblay R, Wang D, Jevnikar AM, Ma S. Tobacco, a highly efficient green bioreactor for production of therapeutic proteins. Biotechnol Adv 2010; 28:214-21. [PMID: 19961918 PMCID: PMC7132750 DOI: 10.1016/j.biotechadv.2009.11.008] [Citation(s) in RCA: 90] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2009] [Revised: 11/06/2009] [Accepted: 11/19/2009] [Indexed: 01/06/2023]
Abstract
Molecular farming of pharmaceuticals in plants has the potential to provide almost unlimited amounts of recombinant proteins for use in disease diagnosis, prevention or treatment. Tobacco has been and will continue to be a major crop for molecular farming and offers several practical advantages over other crops. It produces significant leaf biomass, has high soluble protein content and is a non-food crop, minimizing the risk of food-chain contamination. This, combined with its flexibility and highly-efficient genetic transformation/regeneration, has made tobacco particularly well suited for plant-based production of biopharmaceutical products. The goal of this review is to provide an update on the use of tobacco for molecular farming of biopharmaceuticals as well the technologies developed to enhance protein production/purification/efficacy. We show that tobacco is a robust biological reactor with a multitude of applications and may hold the key to success in plant molecular farming.
Collapse
Affiliation(s)
- Reynald Tremblay
- Department of Biology, University of Western Ontario, London, Ontario, Canada N6A 5B7
| | - David Wang
- Department of Molecular Biology, Princeton University, Princeton, NJ 08544-1014, USA
| | - Anthony M. Jevnikar
- Transplantation Immunology Group, Lawson Health Research Institute, London, Ontario, Canada N6A 4G5
| | - Shengwu Ma
- Department of Biology, University of Western Ontario, London, Ontario, Canada N6A 5B7
- Transplantation Immunology Group, Lawson Health Research Institute, London, Ontario, Canada N6A 4G5
- Plantigen Inc., 700 Collip Circle, London, Ontario, Canada N6G 4X8
| |
Collapse
|
18
|
Karg SR, Kallio PT. The production of biopharmaceuticals in plant systems. Biotechnol Adv 2009; 27:879-894. [PMID: 19647060 DOI: 10.1016/j.biotechadv.2009.07.002] [Citation(s) in RCA: 59] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2009] [Revised: 07/15/2009] [Accepted: 07/17/2009] [Indexed: 12/20/2022]
Abstract
Biopharmaceuticals present the fastest growing segment in the pharmaceutical industry, with an ever widening scope of applications. Whole plants as well as contained plant cell culture systems are being explored for their potential as cheap, safe, and scalable production hosts. The first plant-derived biopharmaceuticals have now reached the clinic. Many biopharmaceuticals are glycoproteins; as the Golgi N-glycosylation machinery of plants differs from the mammalian machinery, the N-glycoforms introduced on plant-produced proteins need to be taken into consideration. Potent systems have been developed to change the plant N-glycoforms to a desired or even superior form compared to the native mammalian N-glycoforms. This review describes the current status of biopharmaceutical production in plants for industrial applications. The recent advances and tools which have been utilized to generate glycoengineered plants are also summarized and compared with the relevant mammalian systems whenever applicable.
Collapse
Affiliation(s)
- Saskia R Karg
- Institute of Microbiology, ETH Zurich, Wolfgang-Pauli Strasse 10, CH-8093 Zürich, Switzerland.
| | - Pauli T Kallio
- Institute of Microbiology, ETH Zurich, Wolfgang-Pauli Strasse 10, CH-8093 Zürich, Switzerland.
| |
Collapse
|
19
|
Calinski A, Classen B, Zoglauer K, Boehm R. IgG stability in fresh and conditioned medium of tobacco (Nicotiana tabacum) and larch (Larix decidua) embryogenic suspension cultures. Biotechnol Lett 2009; 31:771-8. [PMID: 19156360 DOI: 10.1007/s10529-009-9920-9] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2008] [Accepted: 12/18/2008] [Indexed: 10/21/2022]
Abstract
To explore the feasibility of larch (Larix decidua Mill.) embryogenic cell culture as alternative plant expression system, protein stability in fresh and conditioned medium was characterized in this study and compared to tobacco BY2 suspension culture. Fresh and conditioned media were spiked with 1 microg human IgG and IgG content was determined by ELISA after 24 h incubation. In fresh media, IgG recovery rate decreased to 12-23%. Adsorption on vessel walls probably is the best explanation for this IgG loss and EDTA in the medium strongly influenced wall adsorption. A high IgG recovery rate occurred in all conditioned cell culture media (7 or 14 days after inoculation). Changes in the low molecular weight-constitution of conditioned medium, rather than co-secreted polymers, are responsible for IgG stability in the cell suspension cultures.
Collapse
Affiliation(s)
- Anne Calinski
- Institute of Plant Molecular Physiology and Biotechnology, University of Bonn, Karlrobert Kreitenstr. 13, 53115, Bonn, Germany
| | | | | | | |
Collapse
|
20
|
Burtin D, Chabre H, Olagnier B, Didierlaurent A, Couret MN, Comeau D, Wambre E, Laparra H, Van Overtvelt L, Montandon F, Batard T, Jonval V, Lorphelin A, Merle C, Berrouet C, Parry L, Gomord V, Van Ree R, Moingeon P. Production of native and modified recombinant Der p 1 molecules in tobacco plants. Clin Exp Allergy 2009; 39:760-70. [PMID: 19226276 DOI: 10.1111/j.1365-2222.2009.03201.x] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
BACKGROUND As a complex molecule requiring post-translational processing, it has been difficult to produce the Der p 1 major allergen from the Dermatophagoides pteronyssinus house dust mite in a recombinant form. OBJECTIVE Here, we tested whether transgenic tobacco plants are suitable to express Der p 1, either as a wild-type molecule or as variants lacking N-glycosylation sites (Gly(-)) and/or cysteine protease activity (Enz(-)). Methods Using Agrobacterium tumefaciens-based transformation, pro Der p 1 molecules bearing mutations within either the N-glycosylation sites (N34Q, N150Q) and/or the cysteine protease-active site (C132V) were expressed in tobacco plants. After purification by ion exchange chromatography, allergens were characterized using immunoblotting, circular dichroism (CD), as well as basophil and T lymphocyte stimulation assays. RESULTS Four forms of recombinant Der p 1 (i.e. wild-type Gly(+)/Enz(+), as well as Gly(-)/Enz(+), Gly(+)/Enz(-) or Gly(-)/Enz(-) variants) were successfully expressed in tobacco leaves as pro Der p 1 molecules. Spontaneous cleavage of the pro-peptide was observed in tobacco leaf extracts for all forms of recombinant Der p 1 (r Der p 1). CD confirmed that all r Der p 1 molecules, with the exception of the Gly(-)/Enz(-) variant, exhibited secondary structures comparable to the natural protein. A cysteine protease activity was associated only with the Gly(+)/Enz(+) form. All these molecules exhibit a profile similar to natural Der p 1 with respect to IgE immunoreactivity, basophil activation and T cell recognition. CONCLUSION A tobacco plant expression system allows the production of various forms of mature Der p 1, which could be used for diagnostic or immunotherapeutic purposes.
Collapse
Affiliation(s)
- D Burtin
- Meristem Therapeutics, Clermont-Ferrand, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Benchabane M, Saint-Jore-Dupas C, Bardor M, Faye L, Michaud D, Gomord V. Targeting and post-translational processing of human alpha1-antichymotrypsin in BY-2 tobacco cultured cells. PLANT BIOTECHNOLOGY JOURNAL 2009; 7:146-60. [PMID: 19055607 DOI: 10.1111/j.1467-7652.2008.00382.x] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
The post-translational processing of human alpha(1)-antichymotrypsin (AACT) in Bright Yellow-2 (BY-2) tobacco cells was assessed in relation to the cellular compartment targeted for accumulation. As determined by pulse-chase labelling experiments and immunofluorescence microscopy, AACT sent to the vacuole or the endoplasmic reticulum (ER) was found mainly in the culture medium, similar to a secreted form targeted to the apoplast. Unexpectedly, AACT expressed in the cytosol was found in the nucleus under a stable, non-glycosylated form, in contrast with secreted variants undergoing multiple post-translational modifications during their transit through the secretory pathway. All secreted forms of AACT were N-glycosylated, with the presence of complex glycans as observed naturally on human AACT. Proteolytic trimming was also observed for all secreted variants, both during their intracellular transit and after their secretion in the culture medium. Overall, the targeting of human AACT to different compartments of BY-2 tobacco cells led to the production of two protein products: (i) a stable, non-glycosylated protein accumulated in the nucleus; and (ii) a heterogeneous mixture of secreted variants resulting from post-translational N-glycosylation and proteolytic processing. Overall, these data suggest that AACT is sensitive to resident proteases in the ER, the Golgi and/or the apoplast, and that the production of intact AACT in the plant secretory pathway will require innovative approaches to protect its structural integrity in vivo. Studies are now needed to assess the activity of the different AACT variants, and to identify the molecular determinants for the nuclear localization of AACT expressed in the cytosol.
Collapse
Affiliation(s)
- Meriem Benchabane
- Département de Phytologie, Pavillon des Services-INAF, Université Laval, Québec, QC, Canada, G1V 0A6
| | | | | | | | | | | |
Collapse
|
22
|
Sourrouille C, Marshall B, Liénard D, Faye L. From Neanderthal to nanobiotech: from plant potions to pharming with plant factories. Methods Mol Biol 2009; 483:1-23. [PMID: 19183890 DOI: 10.1007/978-1-59745-407-0_1] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
Plants were the main source for human drugs until the beginning of the nineteenth century when plant-derived pharmaceuticals were partly supplanted by drugs produced by the industrial methods of chemical synthesis. During the last decades of the twentieth century, genetic engineering has offered an alternative to chemical synthesis, using bacteria, yeasts and animal cells as factories for the production of therapeutic proteins. After a temporary decrease in interest, plants are rapidly moving back into human pharmacopoeia, with the recent development of plant-based recombinant protein production systems offering a safe and extremely cost-effective alternative to microbial and mammalian cell cultures. In this short review, we will illustrate that current improvements in plant expression systems are making them suitable as alternative factories for the production of either simple or highly complex therapeutic proteins.
Collapse
|
23
|
Abstract
Plants have emerged in the past decade as a suitable alternative to the current production systems for recombinant pharmaceutical proteins and, today their potential for low-cost production of high quality, much safer and biologically active mammalian proteins is largely documented. Among various plant expression systems being explored, genetically modified suspension-cultured plant cells offer a promising system for production of biopharmaceuticals. Indeed, when compared to other plant-based production platforms that have been explored, suspension-cultured plant cells have the advantage of being totally devoid of problems associated with the vagaries of weather, pest, soil and gene flow in the environment. Because of short growth cycles, the timescale needed for the production of recombinant proteins in plant cell culture can be counted in days or weeks after transformation compared to months needed for the production in transgenic plants. Moreover, recovery and purification of recombinant proteins from plant biomass is an expensive and technically challenging business that may amount to 80-94% of the final product cost. One additional advantage of plant cell culture is that the recombinant protein fused with a signal sequence can be expressed and secreted into the culture medium, and therefore recovered and purified in the absence of large quantities of contaminating proteins. Consequently, the downstream processing of proteins extracted from plant cell culture medium is less expensive, which may/does balance the higher costs of fermentation. When needed for clinical use, recombinant proteins are easily produced in suspension-cultured plant cells under certified, controllable and sterile conditions that offer improved safety and provide advantages for good manufacturing practices and regulatory compliance. In this chapter, we present basic protocols for rapid generation of transgenic suspension-cultured cells of Nicotiana tabacum, Oriza sativa and Arabidopis thaliana. These systems are powerful tools for plant-made pharmaceuticals production in highly controlled conditions.
Collapse
|
24
|
|
25
|
Schmidt G, Gadermaier G, Pertl H, Siegert M, Oksman-Caldentey KM, Ritala A, Himly M, Obermeyer G, Ferreira F. Production of recombinant allergens in plants. PHYTOCHEMISTRY REVIEWS : PROCEEDINGS OF THE PHYTOCHEMICAL SOCIETY OF EUROPE 2008; 7:539-552. [PMID: 21258627 PMCID: PMC3024541 DOI: 10.1007/s11101-008-9099-z] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/14/2023]
Abstract
A large percentage of allergenic proteins are of plant origin. Hence, plant-based expression systems are considered ideal for the recombinant production of certain allergens. First attempts to establish production of plant-derived allergens in plants focused on transient expression in Nicotiana benthamiana infected with recombinant viral vectors. Accordingly, allergens from birch and mugwort pollen, as well as from apple have been expressed in plants. Production of house dust mite allergens has been achieved by Agrobacterium-mediated transformation of tobacco plants. Beside the use of plants as production systems, other approaches have focused on the development of edible vaccines expressing allergens or epitopes thereof, which bypasses the need of allergen purification. The potential of this approach has been convincingly demonstrated for transgenic rice seeds expressing seven dominant human T cell epitopes derived from Japanese cedar pollen allergens. Parallel to efforts in developing recombinant-based diagnostic and therapeutic reagents, different gene-silencing approaches have been used to decrease the expression of allergenic proteins in allergen sources. In this way hypoallergenic ryegrass, soybean, rice, apple, and tomato were developed.
Collapse
Affiliation(s)
- Georg Schmidt
- Christian Doppler Laboratory for Allergy Diagnosis and Therapy, Department of Molecular Biology, University of Salzburg, Hellbrunnerstr. 34, 5020 Salzburg, Austria
| | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Benchabane M, Goulet C, Rivard D, Faye L, Gomord V, Michaud D. Preventing unintended proteolysis in plant protein biofactories. PLANT BIOTECHNOLOGY JOURNAL 2008; 6:633-48. [PMID: 18452504 PMCID: PMC7159130 DOI: 10.1111/j.1467-7652.2008.00344.x] [Citation(s) in RCA: 147] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/20/2007] [Revised: 03/13/2008] [Accepted: 03/21/2008] [Indexed: 05/18/2023]
Abstract
Numerous reports have been published over the last decade assessing the potential of plants as useful hosts for the heterologous expression of clinically useful proteins. Significant progress has been made, in particular, in optimizing transgene transcription and translation in plants, and in elucidating the complex post-translational modifications of proteins typical of the plant cell machinery. In this article, we address the important issue of recombinant protein degradation in plant expression platforms, which directly impacts on the final yield, homogeneity and overall quality of the resulting protein product. Unlike several more stable and structurally less complex pharmaceuticals, recombinant proteins present a natural tendency to structural heterogeneity, resulting in part from the inherent instability of polypeptide chains expressed in heterologous environments. Proteolytic processing, notably, may dramatically alter the structural integrity and overall accumulation of recombinant proteins in plant expression systems, both in planta during expression and ex planta after extraction. In this article, we describe the current strategies proposed to minimize protein hydrolysis in plant protein factories, including organ-specific transgene expression, organelle-specific protein targeting, the grafting of stabilizing protein domains to labile proteins, protein secretion in natural fluids and the co-expression of companion protease inhibitors.
Collapse
|
27
|
Liénard D, Sourrouille C, Gomord V, Faye L. Pharming and transgenic plants. BIOTECHNOLOGY ANNUAL REVIEW 2007; 13:115-47. [PMID: 17875476 DOI: 10.1016/s1387-2656(07)13006-4] [Citation(s) in RCA: 54] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Plant represented the essence of pharmacopoeia until the beginning of the 19th century when plant-derived pharmaceuticals were partly supplanted by drugs produced by the industrial methods of chemical synthesis. In the last decades, genetic engineering has offered an alternative to chemical synthesis, using bacteria, yeasts and animal cells as factories for the production of therapeutic proteins. More recently, molecular farming has rapidly pushed towards plants among the major players in recombinant protein production systems. Indeed, therapeutic protein production is safe and extremely cost-effective in plants. Unlike microbial fermentation, plants are capable of carrying out post-translational modifications and, unlike production systems based on mammalian cell cultures, plants are devoid of human infective viruses and prions. Furthermore, a large panel of strategies and new plant expression systems are currently developed to improve the plant-made pharmaceutical's yields and quality. Recent advances in the control of post-translational maturations in transgenic plants will allow them, in the near future, to perform human-like maturations on recombinant proteins and, hence, make plant expression systems suitable alternatives to animal cell factories.
Collapse
Affiliation(s)
- David Liénard
- Université de Rouen, CNRS UMR 6037, IFRMP 23, GDR 2590, Faculté des Sciences, Bât. Ext. Biologie, 76821 Mont-Saint-Aignan cedex, France
| | | | | | | |
Collapse
|